Company: CERO
Filing Date: 2025-12-05
Form Type: S-1
Source: 0001213900-25-118817
Chunk: 171

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-12-05
Form: S-1
Chunk 171
---
 marrow samples and peripheral blood from AML patients. We screened a preliminary panel of primary, treatment-naïve or on-therapy AML bone marrow and PBMC samples by flow cytometry: (n=5 adverse, n=5 intermediate, n=1 APL, n=1 familial, n=5 N/A) (Table 1). We observed both high percent (35.5 % ± 21.6) and geometric mean fluorescence index (“gMFI”) of cell surface TIM-4-L on a range of AML bone marrow samples. The median gMFI of tertiles 1-3 was: T1 n=7, gMFI = 5033; T2 n=8, gMFI = 1873; T3 n=8, gMFI = 611. Of note, the two on-therapy samples showed high percent and gMFI of cell surface TIM-4-L, with a patient receiving 5-azacytidine showing 1.8 fold TIM-4-L gMFI over median. The second patient receiving TKI therapy showed 3.3 fold TIM-4-L gMFI over median. Healthy donor samples had much lower cell surface TIM-4-L, with a mean gMFI of 582. Circulating AML leukemic blasts were also evaluated for cell surface TIM-4-L and showed high concordance with BM blasts, with high levels of cell surface TIM-4-L compared to healthy donor peripheral blood mononuclear cells (“PBMCs”). 99 Table 1. AML patient characteristics

| Patient:   
 Patient ID |     | Treatment Status: 
 Disease Status    |     | Previous             
 Treatments           |     |    Patient 
     Age At 
 Collection |     | Gender |     | Race  |     | Patient:            
 Ethnicity           |     | % Blast 
   Cells |     | Risk Category |     | Genetic              
 Abnormality          |     | Cytogenetics |
| 200001107  |     | Newly Diagnosed   |     | none                 |     |         67 |     | Female |     | White |     | Non-Hispanic/Latino |     |      91 |     | Adverse       |     | RUNX1                |     | N/A          |
| 200015767  |     | Newly Diagnosed   |     | none                 |     |         59 |     | Female |